Neurorubine (Thiamine Hydrochloride, Cyanocobalamin, Pyridoxine Hydrochloride)

Thiamine hydrochloride acts as a co‑enzyme in the conversion of carbohydrates to energy by participating in the pyruvate dehydrogenase complex. Within Neurorubine, it works together with pyridoxine and cyanocobalamin to facilitate amino‑acid metabolism, neurotransmitter synthesis, and DNA production, thereby supporting cellular energy and nervous system health.

The appropriate dose of Neurorubine is determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of deficiency, route of administration, and individual response. No standard dosing regimen is provided here; clinicians tailor the amount to achieve therapeutic goals while monitoring safety.

Safety data for Neurorubine in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any unknown risks before prescribing to pregnant or nursing women. Consultation with a specialist is recommended to decide whether the injectable B‑vitamin supplementation is appropriate in these situations.

To place an order, submit an enquiry on the Neurorubine product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Neurorubine combines three B‑vitamins in a single injectable formulation, offering a broader spectrum of co‑enzyme support compared with single‑vitamin preparations such as cyanocobalamin alone. This multi‑vitamin approach can simplify dosing schedules and may provide synergistic benefits for metabolic and neurological health, though individual product selection should consider specific clinical needs and physician preference.

Neurorubine should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Maintaining the cold‑chain ensures stability of the vitamin components and preserves product potency.

Neurorubine is supplied as an injectable solution and may be given intra‑articularly, intravenously, or peri‑articularly, depending on the clinical indication. Administration should be performed by qualified healthcare personnel using aseptic technique, with the dosage and route selected by the prescribing clinician.

The most serious adverse events associated with Neurorubine include anaphylactic reactions, severe hypotension immediately after injection, and rare dermatologic conditions such as Stevens‑Johnson syndrome. Prompt recognition of these signs and immediate medical intervention are essential to mitigate potential harm.

Neurorubine should be avoided in individuals with known hypersensitivity to any of its B‑vitamin components, in patients who have experienced severe allergic reactions to similar injectable vitamins, and in those for whom the prescriber determines that the risk outweighs the benefit, such as certain uncontrolled medical conditions.